Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Heptares Therapeutics
Heptares Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Heptares enters drug collaboration with Imperial
Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Research & Development
Heptares enters research and drug discovery collaboration
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, launched a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan
Research & Development
New programme focused on GPCR target implicated in brain cancer
Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine
Research & Development
Heptares plans relocation to Cambridge, UK
Heptares is planning to create a state of the art research and development facility on Granta Park to support its growth strategy
Research & Development
John Daly Lecture Award for Heptares’ co-founder
Heptares’ co-founder and Chief Scientific Officer, Fiona Marshall, receives 2017 John Daly Lecture Award in recognition of her outstanding contribution to GPCR drug discovery
Research & Development
New insights to advance drug discovery in pain, cancer and inflammation
Heptares collaboration with AstraZeneca yields novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules
Subscribe now